Skip to main content

Table 1 Socio-demographic and Clinical characteristics of HIV/AIDs patients in the University of Gondar referral hospital, 2017

From: Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia

Variables Frequency Percent
Age 18–29 54 12.8
30–39 169 40.0
40–49 136 32.2
> = 50 64 15.1
Marital status Single 97 22.9
Married 209 49.4
Divorced 81 19.1
Widowed 36 8.5
Gender Female 272 64.3
Male 151 35.7
Resident Urban 343 81.1
Rural 80 18.9
Occupation Farmer 51 12.1
Merchant 58 13.7
Student 17 4
government employ 43 10.2
daily laborer 62 14.7
house life 101 23.9
Private employ 66 15.6
Other 25 5.9
Educational status Illiterate 121 28.6
primary school 117 27.7
secondary school 142 33.6
Tertiary 43 10.2
Religion Orthodox 386 91.3
Muslim 30 7.1
Protestant 7 1.7
Total 423 100.0
Duration of ART in year <=6 162 38.3
> 6 261 61.7
Mean ART duration in year 7 year (+ 3) 423 100%
Base line WHO stage WHO stage I 57 (13.5)
WHO stage II 97 (22.9)
WHO stage III 214 (50.6)
WHO stage IV 55 (13.0)
WHO stage during data collection WHO stage I 11 (2.6)
WHO stage II 408 (96.5)
WHO stage III 4 (.9)
Type of Opportunistic infection No 308 (72.8)
Protozoa 4 (.9)
Helminths 12 (2.8)
Hepatitis viruses 3 (.7)
fungal infections 1 (.2)
TB 89 (21.0)
Mixed 6 (1.4)
Initial regimen D4T + 3TC + NVP 78 (18.4)
D4T + 3TC+ EFV 29 (6.9)
AZT +3TC + NVP 156 (36.9)
AZT + 3TC + EFV 30 (7.1)
TDF + 3TC + EFV 87 (20.6)
TDF + 3TC + NVP 31 (7.3)
D4T + 3TC + NVP 6 (1.4)
Pediatric 4C (AZT + 3TC + NVP) 6 (1.4)
Switching No 261 (61.7)
Yes 162 (38.3)
Total 423 (100.0)
Switching To 1st line drug 150 (35.5)
To 2nd line drug 12 (2.8)
Second regimen AZT +3TC + NVP 61 37.7
AZT + 3TC + EFV 25 15.4
TDF + 3TC + NVP 25 15.4
TDF + 3TC + EFV 39 24.1
ABC + ddl + LPV/R 11 6.8
TDF + ddl + IPV/R 1 .6
Reason of switching drug Toxicity 109 (67.3)
Pregnancy 7 (4.3)
TB 18 (11.1)
Clinical failure 1 (.6)
Age 9 (5.6)
ARV drug ADH at base line Good 408 (96.5)
Fair 2 (.5)
Poor 13 (3.1)
ARV drug ADH During data collection Good 420 (99.3)
Poor 3 (.7)
Base line CD4 count <=199 267 (63.1)
200–349 120 (28.4)
350–499 27 (6.4)
> = 500 9 (2.1)
CD4 count during data collection <=199 44 (10.4)
200–349 110 (26.0)
350–499 114 (27.0)
> = 500 155 36.6
Viral load count Undetected 224 53.0
0–19 84 19.9
20–999 53 12.5
> = 1000 62 14.7
Total 423 100
Component of immunological failure CD4 Falling More Than 50% 30 53.6
CD4 Falling Below Baseline 21 37.5
CD4 Persistently Below 100 5 8.9
Total 56 100
  1. ADH adherence, ARV Antiretroviral, D4T Stavudine,TDF TenofovirDisoproxilFumarate, AZT/ 3TC Zidovudine/Lamivudine, EFV Efavirenze, NVP Nevirapine, ABC abacavir, ddl didanosine, LPV/R lopinavir/ritonavir, Mixed patients infected with more than two organism